LON:VENN - Venn Life Sciences Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0
+0.30 (1.20%)

This chart shows the closing price for VENN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Venn Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VENN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VENN

Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for Venn Life Sciences in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.

This chart shows the closing price for VENN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Venn Life Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/5/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/29/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Venn Life Sciences

Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: GBX 6.85
Low: 6.85
High: 6.85

52 Week Range

Now: N/A

Volume

1,027,544 shs

Average Volume

566,253 shs

Market Capitalization

£4.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Venn Life Sciences?

The following sell-side analysts have issued reports on Venn Life Sciences in the last twelve months:
View the latest analyst ratings for VENN.

What is the current price target for Venn Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Venn Life Sciences in the last year. has the lowest price target set, forecasting a price of £100,000 for Venn Life Sciences in the next year.
View the latest price targets for VENN.

What is the current consensus analyst rating for Venn Life Sciences?

Venn Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VENN.

What other companies compete with Venn Life Sciences?

How do I contact Venn Life Sciences' investor relations team?

Venn Life Sciences' physical mailing address is 1 Berkeley Street, LONDON, W1J 8DJ, United Kingdom. The company's listed phone number is +44-28-90737900. The official website for Venn Life Sciences is www.vennlifesciences.com.